1-氨基甲酰-1,2,3,4-四氢喹啉 | 63098-90-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 1-氨基甲酰-1,2,3,4-四氢喹啉
• 英文名称: 3,4-dihydro-2H-quinoline-1-carboxylic acid amide
• 英文别名: 3,4-Dihydro-2H-chinolin-1-carbonsaeure-amid；1-Carbamoyl-1,2,3,4-tetrahydroquinoline；3,4-dihydro-2H-quinoline-1-carboxamide
• CAS: 63098-90-8
• 化学式: C₁₀H₁₂N₂O
• 分子量: 176.218
• InChiKey: ZAFBGRNWOGKKSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933499090

反应信息

• 作为产物：
  描述：

  苯胺 在 copper(l) iodide 、 三苯基膦 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 4.0h， 生成 1-氨基甲酰-1,2,3,4-四氢喹啉
  参考文献：
  名称：

  铁催化仲胺，伯醇和三甲基甲硅烷基氰化物对[小α]氨基腈的顺序反应

  摘要：

  首次开发了铁胺催化的仲胺与伯醇，三甲基甲硅烷基氰化物和TBHP在温和的反应条件下进行的顺序反应，一次即可得到相应的α-氨基腈

  DOI：

  10.1039/c5cc10346k

文献信息

• Pyrazole compounds and their use as antidiabetes agents
  申请人：Takagi Masaki

  公开号：US20070032529A1

  公开（公告）日：2007-02-08

  The present invention provides a pyrazole compound that has liver glycogen phosphorylase inhibitory activity and is useful as a therapeutic or prophylactic agent for diabetes, the pyrazole compound represented by the following general formula (I): wherein Ring Q represents an aryl or heteroaromatic group, R 1 represents a hydrogen atom, a halogen atom, a C 1-6 alkyl group or a C 1-6 alkoxy group, R 2 represents a halogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group or an azido group, R 3 represents a halogen atom, a hydroxyl group, a C 1-6 alkyl group, a halo C 1-6 alkyl group, a C 1-6 alkoxy group, an azido group, an amino group, an acylamino group or a C 1-6 alkylsulfonylamino group, R 4 and R 5 are identical with or different from each other and represent a hydrogen atom, a substituted or unsubstituted C 1-6 alkyl group, a C 3-8 cycloalkyl group, a substituted or unsubstituted saturated heterocyclic group, a substituted or unsubstituted aryl group, a C 7-14 aralkyl group, a heteroaromatic group, or the like, or a pharmacologically acceptable salt thereof.

  本发明提供了一种具有肝糖原磷酸化酶抑制活性的吡唑化合物，用作糖尿病的治疗或预防剂，所述吡唑化合物由以下通用式（I）表示：其中环Q代表芳基或杂芳基，R1代表氢原子、卤原子、C1-6烷基或C1-6烷氧基，R2代表卤原子、C1-6烷基、C1-6烷氧基或偶氮基，R3代表卤原子、羟基、C1-6烷基、卤代C1-6烷基、C1-6烷氧基、偶氮基、氨基、酰胺基或C1-6烷基磺酰胺基，R4和R5彼此相同或不同，代表氢原子、取代或未取代的C1-6烷基、取代或未取代的C3-8环烷基、取代或未取代的饱和杂环基、取代或未取代的芳基、C7-14芳基烷基、杂芳基等，或其药理学上可接受的盐。
• NOVEL PARP INHIBITORS
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：EP1582520A1

  公开（公告）日：2005-10-05

  A compound represented by: (wherein R1 represents H, halogen, OH, amino, or C1-4 alkyl or C1-4 alkoxy unsubstituted or substituted by 1 to 5 halogens; n represents 0 to 2; R2 and R3 each represent H, C1-6 alkyl, C2-4 alkenyl, or -L-Ar (L represents a bond or C1-6 alkylene, and Ar represents a saturated or unsaturated 5- or 6-membered ring or saturated or unsaturated 8- to 12-membered condensed-bicyclic hydrocarbon group which does not contain or contain one to three N, S, or O atoms); any group in R1 to R3 may have 1 to 3 substituents selected from group A [halogen, NO2, CN, OH, oxo, and substituted or unsubstituted amino]; X represents - (CHR4) -, - (C=NOR5) - or -C(O)-; R4 represents -NR6R7 (R6 and R7 each represent H, C1-6 alkyl, C1-6 alkylcarbonyl, or the like); R5 represents H or C1-6 alkyl; Y represents -NH- or methylene; Z represents methylene, ethylene or vinylene; and the hydrogen of Y and Z are unsubstituted or substituted by halogen, NO2, alkyl or the like) or a salt thereof, and a pharmaceutical composition containing the compound or the salt. The compound of the present invention has a poly(ADP-ribose)polymerase inhibitory effect, and is safe and advantageous for drug formulation.

  一种由以下表示的化合物：（其中R1代表H、卤素、OH、氨基或未被1至5个卤素取代或取代的C1-4烷基或C1-4烷氧基；n代表0至2；R2和R3各自代表H、C1-6烷基、C2-4烯基，或-L-Ar（L代表键或C1-6烷基，Ar代表不含或含有1至3个N、S或O原子的饱和或不饱和5-或6-成员环或饱和或不饱和8-至12-成员的环状或非环状的融合双环烃基）；R1至R3中的任何基团可能有1至3个从A组[卤素、NO2、CN、OH、氧化物或取代或未取代的氨基]中选择的取代基；X代表-（CHR4）-、-（C=NOR5）-或-C(O)-；R4代表-NR6R7（R6和R7各自代表H、C1-6烷基、C1-6烷基羰基或类似物）；R5代表H或C1-6烷基；Y代表-NH-或亚甲基；Z代表亚甲基、乙烯基或乙烯基；Y和Z的氢未被卤素、NO2、烷基或类似物取代或取代）或其盐，以及含有该化合物或其盐的药物组合物。本发明的化合物具有聚（ADP-核糖）聚合酶抑制作用，并且对于药物制剂是安全且有利的。
• Novel PARP inhibitor
  申请人：Shiromizu Ikuya

  公开号：US20060004028A1

  公开（公告）日：2006-01-05

  A compound represented by: or a salt thereof, and a pharmaceutical composition containing the compound or the salt, the compound having a poly (ADP-ribose)polymerase inhibitory effect, and is safe and advantageous for drug formulation.

  一种化合物，其表示为：或其盐，以及含有该化合物或盐的药物组合物，该化合物具有多聚(ADP核糖)聚合酶抑制作用，并且对于药物制剂来说是安全和有优势的。
• Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands
  申请人：Fukumoto Shoji

  公开号：US20090253687A1

  公开（公告）日：2009-10-08

  The present invention relates to wherein each symbol is as defined in the specification. The compound has a superior mineral corticoidreceptorantagonistic action and is useful as an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like, a compound having a fused heterocycle, or a prodrug thereof, or a salt thereof; and an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like.

  本发明涉及其中每个符号如规范所定义的化合物，该化合物具有优越的矿物质皮质激素受体拮抗作用，可作为预防或治疗高血压、心力衰竭等药物，包括具有融合杂环的化合物、其前药或其盐；以及预防或治疗高血压、心力衰竭等疾病的药剂。
• Triazole Derivative and Use Thereof
  申请人：Kubo Keiji

  公开号：US20090105253A1

  公开（公告）日：2009-04-23

  The present invention relates to a thrombin receptor antagonist containing a compound represented by the formula (I) wherein R 1a , R 1b and R 2 are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or an optionally substituted alkoxy, R 3 is a group represented by the formula —NHCOR 4 , —NHSO 2 R 5 , —NHCON(R 6a )(R 6b ), —NHCOOR 7 or —CONHR 8 wherein R 4 , R 5 , R 6a , R 6b , R 7 and R 8 are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group and the like), ring A is monocyclic aromatic ring optionally further having substituent(s), R 1a and R 1b are optionally bonded to each other to form an optionally substituted nitrogen-containing non-aromatic heterocycle, or a salt thereof or a prodrug thereof. The thrombin receptor antagonist of the present invention has a thrombin receptor (particularly PAR-1) antagonistic action and is useful for the prophylaxis or treatment of PAR-1 mediated pathological condition or disease.

  本发明涉及一种含有式(I)所表示的化合物的凝血酶受体拮抗剂，其中R1a、R1b和R2分别是氢原子、可选取代的碳氢基团、可选取代的杂环基团或可选取代的烷氧基，R3是由式—NHCOR4、—NHSO2R5、—NHCON(R6a)(R6b)、—NHCOOR7或—CONHR8所表示的基团，其中R4、R5、R6a、R6b、R7和R8分别是氢原子、可选取代的碳氢基团、可选取代的杂环基团等，环A是单环芳香环，可选地进一步具有取代基，R1a和R1b可选择性地连接在一起形成可选取代的含氮非芳香杂环，或其盐或前药。本发明的凝血酶受体拮抗剂具有凝血酶受体（特别是PAR-1）拮抗作用，可用于预防或治疗PAR-1介导的病理状态或疾病。